top of page
Margarita Chavez, JD
Board Director
Margarita Chavez, JD, is a seasoned biopharmaceutical executive with over 25 years of dealmaking experience in the healthcare industry, including in biotech licensing, IPOs, and acquisitions. Margarita currently serves on the boards of Aligos Therapeutics (NASD:ALGS) and chairs the Strategy Committee, Newron Pharmaceuticals (SIX:NWRN) and chairs the BD Committee, and Xylo Bio as Board Chair. She is also Managing Partner of Ilustrada Group, a biotech advisory. Margarita served as Managing Director at AbbVie Ventures and was responsible for investments in Morphic Therapeutics (acquired by Lilly for $3.2Bn), Alector Therapeutics (NASD:ALEC), Jnana Therapeutics (acquired by Otsuka for $1.1Bn), and Accent Therapeutics, among others. As a Director on the Licensing & Acquisitions team of Abbott/AbbVie, Margarita was involved in the in-licensing of Oralissa, and the acquisitions of Immuven, Solvay, and the Lupron franchise. Early in her career, Margarita practiced as a corporate and securities lawyer, advising clients on mergers, acquisitions, public and private financings at Brobeck, Phleger & Harrison LLP in Silicon Valley.
bottom of page